Global Anti-Inflammatory Drugs Market by Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologics), by Route of Administration (Oral, Injectable, Topical), by Application (Arthritis Treatment, Inflammatory Bowel Disease, Asthma and Respiratory Diseases, Pain Management); Insights & Forecast (2024 ? 2030)

As per Intent Market Research, the Anti-Inflammatory Drugs Market was valued at USD 85.4 Billion in 2024-e and will surpass USD 126.3 Billion by 2030; growing at a CAGR of 6.7% during 2025 - 2030.

The anti-inflammatory drugs market plays a critical role in managing a range of inflammatory conditions such as arthritis, inflammatory bowel disease, asthma, and respiratory disorders. These drugs are used extensively to alleviate pain, reduce swelling, and prevent the progression of diseases associated with inflammation. The market is driven by the rising prevalence of chronic inflammatory diseases, increasing awareness about treatment options, and growing healthcare access globally. Innovations in drug formulations and the development of biologics are expected to propel the market forward, as more targeted treatments become available for conditions like rheumatoid arthritis and other autoimmune disorders.

As the global aging population expands and lifestyle diseases become more prevalent, the demand for anti-inflammatory drugs continues to grow. This market also benefits from advancements in drug delivery systems, such as oral, injectable, and topical formulations, enabling better patient compliance and targeted therapy, which ultimately enhances the effectiveness of treatments.

NSAIDs Are the Largest Drug Class Due to Broad Usage for Pain and Inflammation

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) constitute the largest drug class in the anti-inflammatory drugs market. These drugs are widely used for the treatment of pain and inflammation associated with a variety of conditions, including arthritis, muscle pain, and acute injuries. NSAIDs work by inhibiting cyclooxygenase (COX) enzymes, which play a key role in the production of inflammatory chemicals in the body. The broad availability of NSAIDs over-the-counter (OTC) further contributes to their dominance in the market, as they are commonly used to treat mild to moderate pain and inflammation.

The wide range of NSAIDs available, from traditional options like ibuprofen and aspirin to newer formulations with fewer gastrointestinal side effects, makes them a go-to choice for both patients and healthcare providers. Their proven efficacy in managing pain and inflammation, combined with their cost-effectiveness, ensures NSAIDs continue to be the most commonly prescribed anti-inflammatory treatment across various healthcare settings.

Hospitals Are the Largest End-Use Industry Due to High Demand for Inflammatory Disease Treatment

Hospitals are the largest end-use industry for anti-inflammatory drugs, driven by the high demand for advanced treatments for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease (IBD), and asthma. These drugs are also crucial for managing post-surgical inflammation and pain, making them a staple in hospital settings. With the increasing prevalence of autoimmune disorders and conditions like osteoarthritis and Crohn’s disease, hospitals continue to be the primary setting for the administration of both conventional and biologic anti-inflammatory therapies.

Hospitals provide the necessary infrastructure and specialist healthcare professionals to administer more complex treatments, including biologics and disease-modifying anti-rheumatic drugs (DMARDs). Additionally, hospitals offer the comprehensive care required for patients with severe and chronic inflammatory conditions, ensuring the ongoing demand for anti-inflammatory drugs in these institutions.

North America Is the Largest Region Due to Advanced Healthcare Infrastructure

North America is the largest region in the anti-inflammatory drugs market, primarily driven by the advanced healthcare infrastructure, high healthcare expenditure, and widespread access to medical treatments. The United States, in particular, accounts for a significant share of the market, owing to the high prevalence of chronic inflammatory diseases, including arthritis and respiratory conditions. Moreover, the region has a well-established healthcare system that supports the widespread use of advanced treatments such as biologics and DMARDs, further fueling market growth.

The presence of leading pharmaceutical companies in North America also contributes to the region’s dominance, as these companies are at the forefront of developing and marketing new anti-inflammatory drugs. As the demand for innovative therapies increases and the aging population grows, North America is expected to maintain its leadership position in the global anti-inflammatory drugs market.

Competitive Landscape and Key Players

The competitive landscape of the anti-inflammatory drugs market includes key players such as Pfizer, Johnson & Johnson, AbbVie, and Novartis, who are leading the development and distribution of anti-inflammatory drugs. These companies have a strong portfolio of NSAIDs, corticosteroids, biologics, and DMARDs, and continue to invest in research and development to bring new, more effective treatments to market. Biologics, such as TNF inhibitors and interleukin inhibitors, are particularly gaining traction for the treatment of conditions like rheumatoid arthritis and IBD, due to their ability to target specific inflammatory pathways.

Competition is also driven by pricing strategies, with generic versions of popular NSAIDs providing cost-effective alternatives to branded drugs. As the demand for personalized and targeted therapies grows, the market is likely to see increased collaboration between pharmaceutical companies, academic institutions, and healthcare providers. These collaborations will focus on developing next-generation anti-inflammatory treatments with fewer side effects and greater efficacy, shaping the future of the market.

Recent Developments:

• Pfizer Inc. launched a new biologic anti-inflammatory drug targeting rheumatoid arthritis, significantly expanding its portfolio in immunology.
• AbbVie Inc. received FDA approval for a new oral corticosteroid aimed at treating chronic inflammatory conditions such as asthma and Crohn’s disease.
• GlaxoSmithKline introduced an over-the-counter NSAID in select markets for relief from minor aches and inflammation.
• Merck & Co., Inc. announced a collaboration with a biotech firm to develop next-generation biologics for the treatment of autoimmune diseases.
• Johnson & Johnson unveiled a new injectable anti-inflammatory drug designed to treat severe rheumatoid arthritis with fewer side effects compared to traditional therapies.

List of Leading Companies:

• Johnson & Johnson
• Pfizer Inc.
• AbbVie Inc.
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb
• GlaxoSmithKline PLC
• Sanofi
• Amgen Inc.
• Eli Lilly and Company
• Roche Holding AG
• Bayer AG
• Cipla Limited
• Horizon Therapeutics
• Mylan Pharmaceuticals Inc.

Report Scope: